3D-printed prednisolone phosphate suppositories with tunable dose and rapid release for the treatment of inflammatory bowel disease

Publication date

2024-01-05

Authors

Kocabas, L. I.ISNI 0000000524010147
Ayyoubi, S.
Tajqurishi, M.
Quodbach, JulianISNI 0000000443513164
Vermonden, TinaISNI 0000000357250265
Kok, Robbert JanORCID 0000-0003-4933-3968ISNI 0000000392754805

Editors

Advisors

Supervisors

Document Type

Article
Open Access logo

License

cc_by

Abstract

Established medicines are often not tailored to the needs of the pediatric population, causing difficulties with administration or dosing. Three-dimensional (3D) printing technology allows novel approaches for compounding of personalized medicine, as is exemplified in this study for the automated compounding of rectal preparations for children. We investigated the material requirements to print prednisolone phosphate-loaded suppositories with tunable dose and rapid drug release for the treatment of inflammatory bowel diseases. Three formulations containing 4 % w/w prednisolone sodium phosphate (PSP) and different amounts of hydroxypropyl cellulose (HPC) and mannitol as excipients were printed as suppositories with a fused deposition modeling (FDM) 3D-printer. Dissolution studies showed that the PSP release rate was increased when higher weight fractions of mannitol were added as a pore former, with 90 % drug release within 30 min for mannitol 48 % w/w. We further printed suppositories with 48 % mannitol with different infill densities and dimensions to tune the dose. Our findings demonstrated that 3D-printed suppositories with PSP doses ranging from 6 to 30 mg could be compounded without notably affecting the dissolution kinetics, ensuring equivalent therapeutic efficacies for different doses.

Keywords

Fused deposition modeling, Hot-melt extrusion, Infill density, Personalized medicine, Rectal administration, Pharmaceutical Science

Citation

Kocabas, L I, Ayyoubi, S, Tajqurishi, M, Quodbach, J, Vermonden, T & Kok, R J 2024, '3D-printed prednisolone phosphate suppositories with tunable dose and rapid release for the treatment of inflammatory bowel disease', International Journal of Pharmaceutics, vol. 649, 123639. https://doi.org/10.1016/j.ijpharm.2023.123639